Frontiers in Neuroscience (Jul 2021)

Nerve Growth Factor Biodelivery: A Limiting Step in Moving Toward Extensive Clinical Application?

  • Giuseppe Alastra,
  • Luigi Aloe,
  • Vito Antonio Baldassarro,
  • Laura Calzà,
  • Laura Calzà,
  • Laura Calzà,
  • Maura Cescatti,
  • Jason Thomas Duskey,
  • Maria Letizia Focarete,
  • Maria Letizia Focarete,
  • Daria Giacomini,
  • Daria Giacomini,
  • Luciana Giardino,
  • Luciana Giardino,
  • Valentina Giraldi,
  • Valentina Giraldi,
  • Luca Lorenzini,
  • Marzia Moretti,
  • Irene Parmeggiani,
  • Michele Sannia,
  • Giovanni Tosi

DOI
https://doi.org/10.3389/fnins.2021.695592
Journal volume & issue
Vol. 15

Abstract

Read online

Nerve growth factor (NGF) was the first-discovered member of the neurotrophin family, a class of bioactive molecules which exerts powerful biological effects on the CNS and other peripheral tissues, not only during development, but also during adulthood. While these molecules have long been regarded as potential drugs to combat acute and chronic neurodegenerative processes, as evidenced by the extensive data on their neuroprotective properties, their clinical application has been hindered by their unexpected side effects, as well as by difficulties in defining appropriate dosing and administration strategies. This paper reviews aspects related to the endogenous production of NGF in healthy and pathological conditions, along with conventional and biomaterial-assisted delivery strategies, in an attempt to clarify the impediments to the clinical application of this powerful molecule.

Keywords